-
Analysts Call Verrica A Buy For Vast Molluscum Opportunity
Tuesday, July 10, 2018 - 4:23pm | 446Read More...Investors who bought into Verrica Pharmaceuticals Inc (NASDAQ: VRCA) at its June 15 IPO are celebrating 13.1-percent returns. The gains should continue, in the view of two new sell-side bulls. The Ratings Bank of America Merrill Lynch analyst Jason Gerberry initiated coverage of Verrica with a Buy...
-
Adamas Pharma's Gocovri Approved, A Welcome Addition To Parkinson's Treatments
Friday, August 25, 2017 - 12:03pm | 695Read More...Adamas Pharmaceuticals Inc (NASDAQ: ADMS) shares were on a tear Friday following that the FDA has approved its GOCOVRI extended release capsules for dyskinesia in patients with Parkinson's disease receiving levodopa-based therapy, with or without dopaminergic medications. At the time of...
-
Cowen Says Ocular Therapeutix's OTX-DP Miss 'Meaningless' To Bull Thesis
Monday, June 6, 2016 - 2:36pm | 242Read More...Shares of Ocular Therapeutix Inc (NASDAQ: OCUL) were trading down more than 42 percent on Monday, after the company announced its second Phase 3 clinical trial evaluating its lead product candidate DEXTENZA (sustained release dexamethasone) for the treatment of ocular itching associated with...
-
Why Cowen Thinks Allergan Has Massive Upside To $400
Tuesday, September 29, 2015 - 10:29am | 265Read More...The share price of Allergan PLC (NYSE: AGN) has declined 17.25 percent over the past month, after having reached a high of $308.995 on August 31. Cowen’s Ken Cacciatore has maintained an Outpeform rating on the company, with a price target of $400. The company has provided its H2:15...
-
Cowen: Shire's Weak Market Sentiment Yields Opportunity
Thursday, September 17, 2015 - 1:57pm | 478Read More...Shares of Shire PLC (ADR) (NASDAQ: SHPG) have lost nearly 10 percent over the past month. Ken Cacciatore of Cowen commented in a note on Thursday that the "mixed reaction" in the stock has created a "compelling opportunity." Cacciatore maintained an Outperform rating and $325 price target on the...
-
Cowen On Shire: 'Add Aggressively'
Tuesday, March 10, 2015 - 3:33pm | 280Read More...Cowen commented on Shire PLC (ADR) (NASDAQ: SHPG) Tuesday and maintained an Outperform rating and $285 price target. Analysts led by Ken Cacciatore continued "to believe there is a substantial under-appreciation for the likely significant revenue and earnings growth inflection for Shire...
-
Cowen Suggests Truth to Allergan Rumors
Saturday, December 21, 2013 - 6:00pm | 142Read More...Traders continue to build up shares of Allergan Inc. (NYSE: AGN) as account analyst suggests truth to yesterday's rumor. Cowen analyst Ken Cacciatore cited legal consultants in his note while reporting that the Allergan patent may be issued as early as 4-5 weeks. Cacciatore noted that the patent...
